Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM11 in Relapsed/Refractory B-cell NHL
NCT02106091Phase 1Terminated
- Sponsor
- Affimed
- Start
- Apr 2014
- Primary completion
- Aug 2018
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of AFM11 in B-cell non-Hodgkin lymphoma, sponsored by Affimed. Primary endpoint: Number of participants with serious and non-serious adverse events up to 8 weeks. Started Apr 2014; status: terminated.
02
Drugs
AFM11
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02106091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106091.